As a part of its global vaccine sharing strategy, the United States will share a ‘substantial’ number of its surplus Covid-19 vaccine doses with India, a US government official said on Friday.
The official, however, said that the US is yet to finalize the exact number of doses that will be allocated to India and as well as other countries.
“We want to be careful about putting a number out there yet, because we want to work on those pieces. I think there will be a substantial number,” Gayle E Smith, US state department coordinator for global Covid response and health security said.
“We have some notional planning, but refinement of the actual numbers will be determined in consultation with the government, health experts, state of their vaccine plans and delivery and with COVAX,” Smith told reporters. The operational work on the type of vaccine that will be shared will have to be worked out with respective countries.
The US will try to match it with the vaccine programmes across various countries, Smith added.
On Thursday, the US government said it plans to share surplus Covid-19 vaccines to lay the ground for increased global coverage and to address real and potential surges, high burdens of disease, and the needs of the most vulnerable countries.
It plans to send the first tranche of 25 million vaccine doses to countries in Asia, Latin America as well as Africa. Three-fourth of the 25 million doses will be shared through COVAX, an international vaccine sharing programme. Of this, select countries in Asia, including India will get seven million doses.
Of the remaining one-fourth or approximately 6 million doses will be targeted toward regional priorities and partner recipients, including Mexico, Canada, Egypt, Jordan, India, among others.
“Our intention is to lead the global vaccine coverage. A lot of work has to be done to actually deliver vaccines. When other countries also share vaccines, then we can get in a position to actually end this global pandemic,” Smith said.
As far as the availability of Astrazeneca vaccine is concerned, Smith said that the availability will depend on the Food and Drug Administration (FDA) clearance, without spelling out any timeline. Since FDA is an autonomous regulatory public health regulatory, the government will not interfere.
The US had in the past said it plans to send 60 million AstraZeneca vaccines to various countries. However, it is still undergoing the control checks by the FDA.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
Source link
